An under-the-radar Bay Area biotech has brought in a $190 million series B with the goal of hatching a clutch of new companies to fly its drug candidates forward.
Discreet biotech Osanni Bio starts making noise with $190M series B for clinical push
You might be interested in …
Unified bilayer membranes with mechanically reinforced interface for stage-adaptive bone regeneration
Biotechnology : nature.com subject feeds **Innovative Unified Bilayer Membranes with Mechanically Reinforced Interface Pave the Way for Stage-Adaptive Bone Regeneration** *By [Your Name]* In a groundbreaking advancement in regenerative medicine, researchers have developed unified bilayer […]
FDA gene therapy regulator Vijay Kumar steps down from leadership role
Vijay Kumar, the acting head of the FDA office that oversees new gene therapies, is stepping down from his role after a year in the job.
BIOHK2026 (Hong Kong International Biotechnology Conference and Exhibition), 9-12 September, Hong Kong – Connecting Global Leaders in Biotechnology
Seeking biotech investment, breakthrough innovations, or a strategic gateway to the Asia-Pacific? The answers await in Hong Kong this September.HONG KONG, July 7, 2026 /PRNewswire/ — The 5th Hong Kong International Biotechnology Conference and Exhibition (BIOHK2026), jointly organized by the Hong Kong Biotechnology Organization and Reed Sinopharm Exhibitions, will take place from September 9 to…